Please check your internet connection and try again.
# Walethmade bromide
## Overview
There is no pharmacological agent known as "Walethmade bromide." It is highly likely this is a typographical error or a phonetic misspelling of **Aclidinium bromide**, **Tiotropium bromide**, or potentially **Umeclidinium bromide** (long-acting muscarinic antagonists—LAMAs).
*Note: Please verify the exact spelling of the medication. The following information assumes an intent to inquire about a LAMA class drug used in obstructive airway diseases.*
## Primary Indications
Maintenance treatment of airflow obstruction in patients with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema.
## Adult Dosing
* **Aclidinium bromide:** 400 mcg inhaled twice daily.
* **Tiotropium bromide (DPI):** 1.25 mcg to 18 mcg once daily depending on the device/formulation.
* **Umeclidinium bromide:** 62.5 mcg inhaled once daily.
*Note: Always verify specific device-labeling doses, as these are not interchangeable.*
## Pediatric Dosing
LAMAs are generally **not indicated** for pediatric populations (under 18 years). Safety and efficacy have not been established.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is typically required, though patients with severe impairment should be monitored for anticholinergic effects.
* **Hepatic Impairment:** Generally no adjustment required; however, clinical data is limited.
## Contraindications
* Hypersensitivity to the specific drug, atropine, or milk proteins (if the inhaler contains lactose).
* Presence of narrow-angle glaucoma or urinary retention (caution advised).
* Not indicated for the relief of acute bronchospasm (rescue therapy).
## Adverse Effects
* **Common:** Nasopharyngitis, upper respiratory tract infection, headache, cough.
* **Serious:** Paradoxical bronchospasm, new or worsening narrow-angle glaucoma, urinary retention, and potential cardiovascular effects (tachycardia/arrhythmia).
## Key Drug Interactions
* **Anticholinergics:** Concomitant use with other anticholinergic medications (e.g., ipratropium, oxybutynin) increases the risk of additive systemic anticholinergic effects (e.g., dry mouth, constipation, urinary retention).
## Monitoring
* Monitor for paradoxical bronchospasm upon the first dose.
* Assess symptom control (breathlessness, exercise tolerance).
* Periodically monitor for signs of ocular discomfort, urinary obstruction, or worsening of COPD symptoms.
## Clinical Pearls
* **Inhalation Technique:** Correct inhaler technique is vital; patients should be counseled on device use at every visit.
* **Rescue Medication:** LAMAs are maintenance controllers only and must not be used as rescue inhalers for acute respiratory distress.
* **Systemic Absorption:** While generally minimal, systemic absorption can occur; caution is advised in patients with existing bladder neck obstruction or prostatic hyperplasia.
***
**Educational Disclaimer:** The information provided above is for educational purposes only and does not constitute medical advice. Because the searched drug name "Walethmade bromide" does not exist in standard pharmacological databases, the information provided is based on typical LAMA-class profiles. Always verify current prescribing information, package inserts, and local institutional protocols before prescribing or administering any medication.
